Form 4: Celularity Insider Lim Kok Thay and Affiliates Secure Millions in Warrants and Promissory Note

Celularity Inc. reported that Director and 10% owner Lim Kok Thay and affiliated entities acquired new and amended warrants to purchase millions of shares, alongside a significant promissory note investment.

Summary

• Director and 10% owner Lim Kok Thay, along with affiliated entities Genting Berhad and Resorts World Inc Pte. Ltd. (RWI), reported significant warrant transactions and a promissory note investment in Celularity Inc.
• RWI acquired new warrants to purchase 500,000 shares of Class A Common Stock at an exercise price of $2.844 per share, representing a 10% discount from the July 24, 2025 closing price. These warrants expire on July 24, 2030.
• RWI also had existing warrants amended and restated, adjusting their exercise price to $2.844 per share (a 10% discount from the July 24, 2025 closing price). These amended warrants cover 300,000 shares (originally $8.1 exercise price), 300,000 shares (originally $5.895 exercise price), and 1,350,000 shares (originally $2.988 exercise price). The original warrants with $2.844 exercise price were also reported as beneficially owned.
• Lim Kok Thay directly received a warrant to purchase 3,700,000 shares of Class A Common Stock at an exercise price of $2.528 per share, a 20% discount from the July 24, 2025 closing price.
• This warrant for 3,700,000 shares was issued in connection with Mr. Lim's purchase of a promissory note from Celularity Inc. for an aggregate principal amount of $6,812,230, bearing interest at 2% per annum and maturing on March 21, 2026.
• The total number of shares underlying warrants beneficially owned by the reporting persons following these transactions is 6,150,000.

Sentiment

Score: 7

Explanation: The filing indicates a significant capital infusion and continued commitment from a major insider and affiliated entities, which is generally positive for a company like Celularity. However, the discounted warrant exercise prices and the need for this financing suggest ongoing capital requirements and potential future dilution.

Positives

• Significant capital injection for Celularity Inc. through a $6,812,230 promissory note from a key insider, Lim Kok Thay.
• Continued commitment and investment from a Director and 10% owner, Lim Kok Thay, and affiliated entities (Genting Berhad, Resorts World Inc Pte. Ltd.), indicating confidence in the company's future.
• The issuance of warrants with exercise prices at a discount to the closing price provides potential future capital if exercised, while also incentivizing the investors.

Negatives

• The warrants were issued at a discount (10% and 20%) to the closing price, which could be dilutive to existing shareholders if exercised.
• The promissory note bears a relatively low interest rate of 2% per annum, which might be below market rates for a company of Celularity's profile, suggesting favorable terms for the insider.
• The need for a promissory note and warrant issuance suggests the company required additional capital.

Risks

• Potential dilution for existing shareholders if the newly issued and amended warrants are exercised.
• The exercisability of the 3.7 million share warrant is contingent on potential CFIUS clearance, introducing regulatory uncertainty and a potential delay in its exercise.

Future Outlook

The exercisability of the 3.7 million share warrant held by Mr. Lim is contingent on receiving clearance from the Committee on Foreign Investment in the United States (CFIUS) if such clearance is required. This introduces a potential future milestone or hurdle for the full realization of the warrant's value.

Industry Context

This filing indicates a capital infusion for Celularity Inc., a biotechnology company. Companies in the biotech sector often rely on external funding, including debt and equity instruments like warrants, to finance research, development, and operational expenses, especially given the long and costly development cycles for new therapies. The involvement of a significant insider and affiliated entities suggests a strategic investment, potentially signaling confidence in the company's long-term prospects within the competitive biotech landscape.

Comparison to Industry Standards

• The issuance of warrants with discounted exercise prices to strategic investors or insiders is a common mechanism for capital raising in early-stage or growth-oriented biotechnology companies, similar to practices seen in companies during their funding rounds.
• The use of a promissory note alongside warrants is also a standard hybrid financing approach, providing immediate capital while offering equity upside to the investor, comparable to structured financing deals observed in other biotech or medtech companies when securing bridge funding or strategic investments.
• The involvement of CFIUS for foreign investment in sensitive technology sectors like biotechnology is a standard regulatory consideration for companies with international investors, similar to reviews faced by other companies with foreign capital.

Related Party Transactions

• Lim Kok Thay, a Director and 10% owner, purchased a $6,812,230 promissory note from Celularity Inc. and received a warrant for 3.7 million shares.
• Resorts World Inc Pte. Ltd. (RWI), indirectly 50% held by Lim Kok Thay and 50% by Genting Berhad (also a 10% owner), was involved in the amendment of existing warrants and the issuance of new warrants.
• These transactions are explicitly stated to be pursuant to a binding term sheet between the Issuer and RWI.

Stakeholder Impact

• Shareholders: Potential future dilution if warrants are exercised, but also benefit from the capital infusion and continued insider support. The discounted exercise prices could be seen as unfavorable.
• Company (Celularity Inc.): Receives crucial capital through the promissory note and potential future capital from warrant exercises, supporting operations and development.

Next Steps

• Potential future exercise of warrants by Resorts World Inc Pte. Ltd. and Lim Kok Thay.
• Maturity of the promissory note on March 21, 2026.
• Potential CFIUS review and clearance for Lim Kok Thay's warrant exercise.

Key Dates

Recommendation

While the capital infusion and continued insider commitment are positive signals for Celularity Inc., the issuance of warrants at discounted prices suggests potential future dilution for existing shareholders. The company's ongoing need for capital, as evidenced by this financing, indicates continued financial challenges. The CFIUS contingency for a large warrant also adds a layer of uncertainty. Given these mixed signals, a 'hold' recommendation is appropriate, advising investors to monitor the company's operational progress and future financing needs closely.

Keywords

Celularity Inc, CELU, Form 4, SEC filing, insider trading, warrants, promissory note, beneficial ownership, Lim Kok Thay, Genting Berhad, Resorts World Inc Pte. Ltd., capital raise, dilution, CFIUS, Class A Common Stock